Lexicon Pharmaceuticals Stock Performance
| LXRX Stock | USD 1.71 0.06 3.64% |
On a scale of 0 to 100, Lexicon Pharmaceuticals holds a performance score of 2. The company secures a Beta (Market Risk) of 2.86, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lexicon Pharmaceuticals will likely underperform. Please check Lexicon Pharmaceuticals' potential upside, accumulation distribution, price action indicator, as well as the relationship between the expected short fall and day median price , to make a quick decision on whether Lexicon Pharmaceuticals' current price movements will revert.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Lexicon Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Lexicon Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 46.3 M | |
| Free Cash Flow | -162.4 M |
Lexicon |
Lexicon Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 173.00 in Lexicon Pharmaceuticals on January 24, 2024 and sell it today you would lose (2.00) from holding Lexicon Pharmaceuticals or give up 1.16% of portfolio value over 90 days. Lexicon Pharmaceuticals is currently generating 0.2509% in daily expected returns and assumes 7.5788% risk (volatility on return distribution) over the 90 days horizon. In different words, 67% of stocks are less volatile than Lexicon, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lexicon Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lexicon Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lexicon Pharmaceuticals, and traders can use it to determine the average amount a Lexicon Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0331
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LXRX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.58 actual daily | 67 67% of assets are less volatile |
Expected Return
| 0.25 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Lexicon Pharmaceuticals is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lexicon Pharmaceuticals by adding it to a well-diversified portfolio.
Lexicon Pharmaceuticals Fundamentals Growth
Lexicon Stock prices reflect investors' perceptions of the future prospects and financial health of Lexicon Pharmaceuticals, and Lexicon Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lexicon Stock performance.
| Return On Equity | -1.68 | ||||
| Return On Asset | -0.51 | ||||
| Operating Margin | (66.58) % | ||||
| Current Valuation | 342.33 M | ||||
| Shares Outstanding | 246.24 M | ||||
| Price To Earning | 21.02 X | ||||
| Price To Book | 5.21 X | ||||
| Price To Sales | 402.90 X | ||||
| Revenue | 1.2 M | ||||
| EBITDA | (171.2 M) | ||||
| Cash And Equivalents | 61.97 M | ||||
| Cash Per Share | 0.34 X | ||||
| Total Debt | 106.06 M | ||||
| Debt To Equity | 0.36 % | ||||
| Book Value Per Share | 0.38 X | ||||
| Cash Flow From Operations | (161.9 M) | ||||
| Earnings Per Share | (0.80) X | ||||
| Total Asset | 229.43 M | ||||
| Retained Earnings | (1.77 B) | ||||
| Current Asset | 171.5 M | ||||
| Current Liabilities | 31.77 M | ||||
About Lexicon Pharmaceuticals Performance
To evaluate Lexicon Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Lexicon Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Lexicon Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Lexicon Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Lexicon's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas. Lexicon Pharmaceutcl operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 87 people.Things to note about Lexicon Pharmaceuticals performance evaluation
Checking the ongoing alerts about Lexicon Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lexicon Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lexicon Pharmaceuticals had very high historical volatility over the last 90 days | |
| Lexicon Pharmaceuticals may become a speculative penny stock | |
| Lexicon Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.2 M. Net Loss for the year was (177.12 M) with loss before overhead, payroll, taxes, and interest of (52.68 M). | |
| Lexicon Pharmaceuticals currently holds about 61.97 M in cash with (161.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.34. | |
| Over 82.0% of the company shares are owned by institutional investors |
- Analyzing Lexicon Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lexicon Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Lexicon Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lexicon Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lexicon Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lexicon Pharmaceuticals' stock. These opinions can provide insight into Lexicon Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexicon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Lexicon Stock analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Lexicon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceuticals. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lexicon Pharmaceuticals is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lexicon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexicon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexicon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.